Andrew Komjathy
Corporate Officer/Principal presso ASTRIA THERAPEUTICS, INC.
Patrimonio netto: 947 $ in data 31/05/2024
Profilo
Andrew A.
Komjathy is currently the Chief Commercial Officer at Astria Therapeutics, Inc. Prior to this, he was the Vice President-Commercial Sales at Alkermes, Inc. from 2014 to 2018, the VP-U.S.
Multiple Sclerosis Business Unit Sales at Genzyme Corp.
from 2012 to 2014, and the VP & GM-North American Commercial Operations at Shire Human Genetic Therapies, Inc. from 2005 to 2012.
Mr. Komjathy received his undergraduate degree from Bucknell University and his MBA from The Leonard N Stern School of Business.
Partecipazioni note in società pubbliche
| Società | Data | Numero di azioni | Valorizzazione | Data di valutazione |
|---|---|---|---|---|
| 08/02/2024 | 100 ( 0.00% ) | 947 $ | 31/05/2024 |
Posizioni attive di Andrew Komjathy
| Società | Posizione | Inizio |
|---|---|---|
| ASTRIA THERAPEUTICS, INC. | Corporate Officer/Principal | 25/09/2019 |
Precedenti posizioni note di Andrew Komjathy
| Società | Posizione | Fine |
|---|---|---|
Alkermes, Inc.
 Alkermes, Inc. Pharmaceuticals: MajorHealth Technology Alkermes, Inc. develops and manufactures pharmaceutical products. It offers medicines for the treatment of central nervous system (CNS) diseases. The company was founded by Michael A. Wall, Floyd E. Bloom, Frederick W. K. Brown, Paul R. Schimmel and Alexander G. Rich in 1987 and is headquartered in Waltham, MA. | Vendite & Marketing | 01/11/2018 |
Genzyme Corp.
 Genzyme Corp. Medical SpecialtiesHealth Technology Genzyme Corp. engages in development and manufacture of specialty therapeutic, surgical and diagnostic product. It serves in the areas of rare genetic diseases, multiple sclerosis, cardiovascular diseases and endocrinology. The company was founded on June 8, 1981 and is headquartered in Cambridge, MA. | Vendite & Marketing | 01/01/2014 |
Shire Human Genetic Therapies, Inc.
 Shire Human Genetic Therapies, Inc. Medical SpecialtiesHealth Technology Shire Human Genetic Therapies, Inc. develops medicines for the treatment of genetic diseases. The company was founded on July 7, 1988 and is headquartered in Lexington, MA. | Corporate Officer/Principal | 01/01/2012 |
Formazione di Andrew Komjathy
| The Leonard N Stern School of Business | Masters Business Admin |
| Bucknell University | Undergraduate Degree |
Esperienze
Posizioni ricoperte
Attive
Inattive
Società quotate in Borsa
Aziende private
Relazioni
Relazioni di 1° grado
Aziende connesse in 1º grado
Uomo
Donna
Amministratori
Dirigenti
Società collegate
| Società quotate in Borsa | 1 |
|---|---|
| ASTRIA THERAPEUTICS, INC. | Health Technology |
| Aziende private | 3 |
|---|---|
Alkermes, Inc.
Alkermes, Inc. Pharmaceuticals: MajorHealth Technology Alkermes, Inc. develops and manufactures pharmaceutical products. It offers medicines for the treatment of central nervous system (CNS) diseases. The company was founded by Michael A. Wall, Floyd E. Bloom, Frederick W. K. Brown, Paul R. Schimmel and Alexander G. Rich in 1987 and is headquartered in Waltham, MA. | Health Technology |
Genzyme Corp.
Genzyme Corp. Medical SpecialtiesHealth Technology Genzyme Corp. engages in development and manufacture of specialty therapeutic, surgical and diagnostic product. It serves in the areas of rare genetic diseases, multiple sclerosis, cardiovascular diseases and endocrinology. The company was founded on June 8, 1981 and is headquartered in Cambridge, MA. | Health Technology |
Shire Human Genetic Therapies, Inc.
Shire Human Genetic Therapies, Inc. Medical SpecialtiesHealth Technology Shire Human Genetic Therapies, Inc. develops medicines for the treatment of genetic diseases. The company was founded on July 7, 1988 and is headquartered in Lexington, MA. | Health Technology |
- Borsa valori
- Insiders
- Andrew Komjathy
